- Home
- ANAB vs ABL Comparison
ANAB vs ABL Comparison
Compare ANAB & ABL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- ABL
- Stock Information
- Founded
- ANAB 2005
- ABL 2004
- Country
- ANAB United States
- ABL United States
- Employees
- ANAB N/A
- ABL N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- ABL Investment Managers
- Sector
- ANAB Health Care
- ABL Finance
- Exchange
- ANAB Nasdaq
- ABL Nasdaq
- Market Cap
- ANAB 759.5M
- ABL 853.6M
- IPO Year
- ANAB 2017
- ABL N/A
- Fundamental
- Price
- ANAB $22.23
- ABL $7.73
- Analyst Decision
- ANAB Buy
- ABL Strong Buy
- Analyst Count
- ANAB 10
- ABL 4
- Target Price
- ANAB $42.25
- ABL $13.63
- AVG Volume (30 Days)
- ANAB 559.5K
- ABL 453.4K
- Earning Date
- ANAB 05-05-2025
- ABL 05-08-2025
- Dividend Yield
- ANAB N/A
- ABL N/A
- EPS Growth
- ANAB N/A
- ABL N/A
- EPS
- ANAB N/A
- ABL N/A
- Revenue
- ANAB $111,872,000.00
- ABL $134,575,948.00
- Revenue This Year
- ANAB N/A
- ABL $65.34
- Revenue Next Year
- ANAB $9.72
- ABL $25.72
- P/E Ratio
- ANAB N/A
- ABL N/A
- Revenue Growth
- ANAB 387.20
- ABL 73.39
- 52 Week Low
- ANAB $12.21
- ABL $6.34
- 52 Week High
- ANAB $41.31
- ABL $12.40
- Technical
- Relative Strength Index (RSI)
- ANAB 62.32
- ABL 34.93
- Support Level
- ANAB $20.50
- ABL $7.90
- Resistance Level
- ANAB $22.84
- ABL $8.50
- Average True Range (ATR)
- ANAB 1.28
- ABL 0.28
- MACD
- ANAB 0.12
- ABL -0.15
- Stochastic Oscillator
- ANAB 83.24
- ABL 9.49
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.